Revance Therapeutics, Inc.

DAXXIFY

Manufacturer:

Revance Therapeutics, Inc.

Daxxify HCPCS:

J0589

HCPCS Code Descriptor:

Injection, daxibotulinumtoxina-lanm, 1 unit

Category:

J Code

Daxxify NDCs:

72960-0112-01

Primary Type:

Dermatology

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Intramuscular

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Daxxify:

DAXXIFY is aligned to the J Code: J0589. DAXXIFY is a Dermatology medication produced by Revance Therapeutics, Inc. and administered via the Intramuscular route of administration.

ACCESS PRICING AND MORE BY REGISTERING

J0589 Added Date:

4/1/24

J0589 Effective Date:

4/1/24

J0589 Deactive Date:

HCPCS Active

We have not yet identified a manufacturer source of billing and coding information for Daxxify
Our team did not identify a source for Daxxify patient assistance information. Please reach out to our team if you feel that this is a mistake.
DAXXIFY prescribing information can be found at the link below:
Information regarding DAXXIFY’s potential side effects can be found at MedlinePlus